Dr. Sartor on Radium-223 in Early Prostate Cancer

Oliver Sartor, MD
Published: Wednesday, Apr 04, 2012



Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the focus of the phase III ALSYMPCA trial that examined radium-223 (Alpharadin), an experimental radiopharmaceutical for prostate cancer with bone metastases.

Patients enrolled to the trial had either received prior chemotherapy or were chemotherapy naïve. Approximately 43% of patients had not received prior chemotherapy.

The goal of the trial was to find a less toxic alternative to chemotherapy that could be introduced at earlier phases in the treatment process. The current standard treatment for low-risk prostate cancer is active surveillance.

Finding a treatment for early prostate cancer is currently an area of high importance and Sartor believes radium-223 could be effective in this space. However, more research is needed to confirm its efficacy.

SELECTED
LANGUAGE


Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the focus of the phase III ALSYMPCA trial that examined radium-223 (Alpharadin), an experimental radiopharmaceutical for prostate cancer with bone metastases.

Patients enrolled to the trial had either received prior chemotherapy or were chemotherapy naïve. Approximately 43% of patients had not received prior chemotherapy.

The goal of the trial was to find a less toxic alternative to chemotherapy that could be introduced at earlier phases in the treatment process. The current standard treatment for low-risk prostate cancer is active surveillance.

Finding a treatment for early prostate cancer is currently an area of high importance and Sartor believes radium-223 could be effective in this space. However, more research is needed to confirm its efficacy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x